1ROSSI G,PELIZZARI A,MOTTA M,et al.Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with lymphoid malignancies tresated with chemotherapy[J].Br J Haematol,2001,115:58-62.
2YEO W,jOHNSON PJ.Diagnosis,prevention and management of hepatitis B virus reactivation during anticancer therapy[J].Hepatology,2006,43:209-220.
2Yeo W,Johnson PJ.Diagnosis,prevention and management of hepatitis B virus reactivation during anticancer therapy.Hepatology,2006,43:209-220.
3Yeo W,Zee B,Zhong S,et al.Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.Br J Cancer,2004,90:1306-1311.
4Jang JW,Choi JY,Bae SH,et al.Transarterial chemolipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma.J Hepatol,2004,41:427-435.
5Park JW,Park KW,Cho SH,et al.Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma:report of a prospective study.Am J Gastroenterol,2005,100:2194-2200.
6Lin PC,Poh SB,Lee MY,et al.Fatal fulminant hepatitis B after withdrawal of prophylactic lamivudine in hematopoietic stem cell transplantation patients.Int J Hematol,2005,81:349-351.
7Hsiao LT,Chiou TJ,Liu JH,et al.Extended lamivudine therapy against hepatitis B virus infection in hematopoietic stem cell transplant recipients.Biol Blood Marrow Transplant,2006,12:84-94.
8Lee WC,Wu MJ,Cheng CH,et al.Lamivudine is effective for the treatment of reactivation of hepatitis B virus and fulminant hepatic failure in renal transplant recipients.Am J Kidney Dis,2001,38:1074-1081.
9Onwubalili JK.Fulminant hepatic failure in nephrotic syndrome related to withdrawal of immunosuppressive therapy.Postgrad Med J,1988,64:325-327.
10Law JK,Ho JK,Hoskins PJ,et al.Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigennegative,hepatitis B core antibody-positive patient:potential implications for future prophylaxis recommendations.Leuk Lymphoma,2005,46:1085-1089.
